Arranging funding for Somavert

Understand how to access funding for Somavert within your area

Somavert is funded directly by a NHS England specialised commissioning budget via the Blueteq system1

  • Somavert is excluded from the Payment by Results (PbR) tariff
  • It is not funded through the hospital budget
  • All prescribers for new patients must be registered on the Blueteq system
  • Approval must be granted via Blueteq before prescribing to new patients
  • The hospital pharmacist has an integral role in managing and supporting this process
To complete a funding application for Somavert and receive automatic approval you will need to confirm that the patient meets each of the 6 criteria for NHS England funding:1,2
  • Active acromegaly (continued clinical features of acromegaly (disfiguration, metabolic))
  • Decision to start treatment made by pituitary MDT
  • IGF-I ≥1.3xULN
  • Incomplete response or unsuitable for pituitary surgery
  • Incomplete response to somatostatin analogue ± radiotherapy (SRS/SRT) or significant adverse drug reactions
  • Will not be given with somatostatin analogue

To see the full inclusion and exclusion criteria for pegvisomant, visit the clinical commissioning policy here (page 17)

Patients who do not meet the criteria but are funded by an individual funding request (IFR) will continue to receive funding via that route and do not need inclusion into Blueteq

 

See this step-by-step guide to completing a funding application via Blueteq

Using Blueteq to apply for Somavert funding
This animation explains how to set up a new user account on Blueteq and what information is needed

 

 

 

References

  1. NHS England A03X01/01 Clinical Commissioning Policy Proposition. December 2016. Available at: https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16050P.pdf (last accessed August 2020).
  2. Somavert Summary of Product Characteristics. July 2020. Available at: https://www.medicines.org.uk/emc/product/64/smpc (last accessed August 2020).

PP-SOM-GBR-0630. August 2020.

Somavert is reimbursed by NHSE, AWMSG and SMC

Wales1

Image of the Welsh flag

In November 2017, the All Wales Medicines Strategy Group recommended Somavert as a third-line treatment of acromegaly in adults

  • Somavert is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs didn’t normalise IGF-I concentrations or was not tolerated
  • Under the guidance, any prescribing centre can prescribe Somavert. However, this should usually be undertaken only after appropriate review in a pituitary MDT

Scotland2

Image of the Scottish flag

Following a second resubmission considered under the ultra-orphan process, pegvisomant (Somavert) is accepted for use within NHS Scotland

  • For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated
  • SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting

Northern Ireland3

Image of the flag of Northern Ireland

In Northern Ireland, pegvisomant (Somavert) is accepted for use

  • For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated
  • This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in Northern Ireland or a list price that is equivalent or lower

 

 

 

References

  1. All Wales Medicines Strategy Group. November 2017. Available at: http://www.awmsg.org/awmsgonline/app/appraisalinfo/3545 (last accessed August2020).
  2. Scottish Medicines Consortium. November 2017. Available at: https://www.scottishmedicines.org.uk/medicines-advice/pegvisomant-somave... (last accessed August2020).
  3. Northern Ireland Formulary. January 2018. https://niformulary.hscni.net/managed-entry/managed-entry-decisions/ (last accessed August 2020).

PP-SOM-GBR-0630. August 2020.

Somavert NHS England commissioning policy
Dr Simon Aylwin, King's College Hospital, Endocrinology CRG, explains the NHSE policy for pegvisomant and its place in the treatment journey for acromegaly patients
Learn about the pharmacist's role with Blueteq
Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and Blueteq funding arrangements to homecare service provision
Discover the full series of Acromegaly Expert Webinars >